HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity
Department of Pain Research, Neuroscience Drug Discovery, Merck Research Laboratories, West Point, Philadelphia, USA
Molecular Pain 2008, 4:48 doi:10.1186/1744-8069-4-48Published: 27 October 2008
Additional file 1:
Table 1: In-vitro pharmacological selectivity of HC-030031. Radioligand binding or enzymatic assays results are summarized as the percent inhibition of specific binding or enzymatic activity. HC-030031 exhibited no significant activity in all assays employed (significance criteria is ≥ 50% of maximal stimulation or inhibition; MDS Pharma Service, Taipei, Taiwan.).
Format: PDF Size: 31KB Download file
This file can be viewed with: Adobe Acrobat Reader